Phase 3 Trial On Ketamine Therapy Gets Almost $2M From UK State Funding
Biotech psychedelics company Awakn Life Sciences Corp. (OTCQB: AWKNF) has been granted funding for 66% of the costs from its phase 3 clinical trial on
Awakn Life Sciences: Business And Corporate Update For Psychedelics Biotech
Biotech psychedelics company Awakn Life Sciences Corp. (OTCQB: AWKNF) has just published its business and corporate updates.